Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2015 December;67(6) > Minerva Ginecologica 2015 December;67(6):557-74

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEWS   

Minerva Ginecologica 2015 December;67(6):557-74

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Drug therapy for overactive bladder

Izett M., Zacchè M., Giarenis I., Robinson D., Cardozo L.

Department of Urogynecology, King’s College Hospital NHS Foundation Trust, London, UK


PDF


Overactive bladder is a syndrome with a significant worldwide prevalence and economic impact on health resources. With ageing populations, the health burden of this condition that is more common in older people, is likely to increase. Following conservative therapies, medical management of overactive bladder is the mainstay of treatment, usually with antimuscarinic therapy. However, adherence is poor either due to adverse events or lack of efficacy of therapy. There have been recent developments that include a β3-adrenoreceptor agonist and intradetrusor botulinum toxin, both of which are increasingly supported by a robust evidence base. Additionally there are emerging combination therapies and novel target agents that aim to treat this troubling syndrome. Alternative modes of delivery for existing therapies are also being explored with a view to improving adherence and efficacy. This article aims to outline the evidence base for existing and novel therapies as well as inform readers of emerging therapeutic options.

inizio pagina